Design and synthesis of novel human epidermal growth factor receptor 2 (HER2)/epidermal growth factor receptor (EGFR) dual inhibitors bearing a pyrrolo[3,2-d]pyrimidine scaffold

Journal of Medicinal Chemistry

Volumn 54, Issue 23, 2011, Pages 8030-8050

  Ishikawa, Tomoyasu ^a   Seto, Masaki ^a   Banno, Hiroshi ^a   Kawakita, Youichi ^a   Oorui, Mami ^a   Taniguchi, Takahiko ^a   Ohta, Yoshikazu ^a   Tamura, Toshiya ^a   Nakayama, Akiko ^a   Miki, Hiroshi ^a   Kamiguchi, Hidenori ^a   Tanaka, Toshimasa ^a   Habuka, Noriyuki ^a   Sogabe, Satoshi ^a   Yano, Jason ^b   Aertgeerts, Kathleen ^b   Kamiyama, Keiji ^a  

^a TAKEDA PHARMACEUTICAL COMPANY LIMITED   (Japan)

^b Takeda San Diego Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 (4 AMINO 2 CHLOROPHENOXY)BENZONITRILE; 2 [2 CHLORO 4 (5H PYRROLO[3,2 D]PYRIMIDIN 4 YLAMINO)PHENOXY]BENZONITRILE; 3 (4 AMINO 2 CHLOROPHENOXY)BENZONITRILE; 3 [2 CHLORO 4 (5H PYRROLO[3,2 D]PYRIMIDIN 4 YLAMINO)PHENOXY]BENZONITRILE; 3 CHLORO 4 (2 CHLOROPHENOXY)ANILINE; 3 CHLORO 4 (2 FLUOROPHENOXY)ANILINE; 3 CHLORO 4 (3 FLUOROPHENOXY)ANILINE; 3 CHLORO 4 (3 METHOXYPHENOXY)ANILINE; 3 CHLORO 4 (3 METHYLPHENOXY)ANILINE; 3 CHLORO 4 [2 (TRIFLUOROMETHOXY)PHENOXY]ANILINE; 3 CHLORO 4 [2 (TRIFLUOROMETHYL)PHENOXY]ANILINE; 3 CHLORO 4 [3 (TRIFLUOROMETHOXY)PHENOXY]ANILINE; 3 CHLORO 4 [3 (TRIFLUOROMETHYL)PHENOXY]ANILINE; 3 CHLORO 4 PHENOXYANILINE; 4 (4 AMINO 2 CHLOROPHENOXY)BENZONITRILE; 4 [2 CHLORO 4 (5H PYRROLO[3,2 D]PYRIMIDIN 4 YLAMINO)PHENOXY]BENZONITRILE; 5 CHLORO 6 [3 (TRIFLUOROMETHYL)PHENOXY]PYRIDIN 3 AMINE; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; N (3 CHLORO 4 PHENOXYPHENYL) 5H PYRROLO[3,2 D]PYRIMIDIN 4 AMINE; N [2 [4 [[3 CHLORO 4 [3 (TRIFLUOROMETHYL)PHENOXY]PHENYL]AMINO] 5H PYRROLO[3,2-D]PYRIMIDIN-5-YL]ETHYL] 3 HYDROXY 3 METHYLBUTANAMIDE; N [3 CHLORO 4 (2 CHLOROPHENOXY)PHENYL] 5H PYRROLO[3,2 D]PYRIMIDIN 4 AMINE; N [3 CHLORO 4 (2 FLUOROPHENOXY)PHENYL] 5H PYRROLO[3,2 D]PYRIMIDIN 4 AMINE; N [3 CHLORO 4 (3 CHLOROPHENOXY)PHENYL] 5H PYRROLO[3,2 D]PYRIMIDIN 4 AMINE; N [3 CHLORO 4 (3 FLUOROPHENOXY)PHENYL] 5H PYRROLO[3,2 D]PYRIMIDIN 4 AMINE; N [3 CHLORO 4 (3 METHYLPHENOXY)PHENYL] 5H PYRROLO[3,2 D]PYRIMIDIN 4 AMINE; N [3 CHLORO 4 [2 (TRIFLUOROMETHYL)PHENOXY]PHENYL] 5H PYRROLO[3,2 D]PYRIMIDIN 4 AMINE; N [3 CHLORO 4 [3 (TRIFLUOROMETHOXY)PHENOXY]PHENYL] 5H PYRROLO[3,2 D]PYRIMIDIN 4 AMINE; N [3 CHLORO 4 [3 (TRIFLUOROMETHYL)PHENOXY]PHENYL] 5H PYRROLO[3,2 D]PYRIMIDIN 4 AMINE; PYRROLO[3,2 D]PYRIMIDINE DERIVATIVE; TAK 285; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BINDING SITE; CANCER INHIBITION; CRYSTAL STRUCTURE; DOSE RESPONSE; DRUG BINDING; DRUG BIOAVAILABILITY; DRUG DESIGN; DRUG RECEPTOR BINDING; DRUG STRUCTURE; DRUG SYNTHESIS; EX VIVO STUDY; MOUSE; NONHUMAN; RAT; STOMACH CANCER; TUMOR XENOGRAFT; X RAY CRYSTALLOGRAPHY;

ADENOSINE TRIPHOSPHATE; ANIMALS; ANTINEOPLASTIC AGENTS; BICYCLO COMPOUNDS, HETEROCYCLIC; BINDING SITES; BIOLOGICAL AVAILABILITY; CELL LINE, TUMOR; CRYSTALLOGRAPHY, X-RAY; DRUG SCREENING ASSAYS, ANTITUMOR; FEMALE; HUMANS; HYDROXYBUTYRATES; MICE; MICE, INBRED BALB C; MODELS, MOLECULAR; NEOPLASM TRANSPLANTATION; PROTEIN CONFORMATION; PYRIMIDINES; PYRROLES; RATS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; STRUCTURE-ACTIVITY RELATIONSHIP; TRANSPLANTATION, HETEROLOGOUS;

EID: 82555187407     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm2008634     Document Type: Article

References (55)

1. Yamamoto, T.; Nishida, T.; Miyajima, N.; Kawai, S.; Ooi, T.; Toyoshima, K. The erbB gene of avian erythroblastosis virus is a member of the src gene family Cell 1983, 35, 71-78
2. Traxler, P. Tyrosine kinases as targets in cancer therapy-successes and failures Expert Opin. Ther. Targets 2003, 7, 215-234
3. Nagar, B.; Bornmann, W. G.; Pellicena, P.; Schindler, T.; Veach, D. R.; Miller, W. T.; Clarkson, B.; Kuriyan, J. Crystal Structures of the Kinase Domain of c-Abl in Complex with the Small Molecule Inhibitors PD173955 and Imatinib (STI-571) Cancer Res. 2002, 62, 4236-4243
4. Burgess, A. W.; Cho, H. S.; Eigenbrot, C.; Ferguson, K. M.; Garrett, T. P.; Leahy, D. J.; Lemmon, M. A.; Sliwkowski, M. X.; Ward, C. W.; Yokoyama, S. An Open-and-Shut Case? Recent Insights into the Activation of EGF/erbB2 Receptors Mol. Cell 2003, 12, 541-552
5. Olayioye, M. A.; Neve, R. M.; Lane, H. A.; Hynes, N. E. The ErbB signaling network: receptor heterodimerization in development and cancer EMBO J. 2000, 19, 3159-3167
6. Hynes, N. E.; Stern, D. F. The biology of erbB-2/neu/HER-2 and its role in cancer Biochim. Biophys. Acta 1994, 1198, 165-184
7. Woodburn, J. R.; Barker, A. J.; Gilson, K. H.; Ashton, S. E.; Wakeling, A. E.; Curry, B. J.; Scarlett, L.; Henthom, L. R. #4251 ZD 1839, an epidermal growth factor tyrosine kinase inhibitor selected for clinical trial development Proc. Am. Assoc. Cancer Res. 1997, 38, 633
8. Barker, A. J.; Gibson, K. H.; Grundy, W.; Godfrey, A. A.; Barlow, J. J.; Healy, M. P.; Woodburn, J. R.; Ashton, S. E.; Curry, B. J.; Scarlett, L.; Henthorn, L.; Richards, L. Studies Leading to the Identification of ZD1839 (Iressa): An Orally Active, Selective Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Targeted to the Treatment of Cancer Bioorg. Med. Chem. Lett. 2001, 11, 1911-1914
9. Wakeling, A. E.; Guy, S. P.; Woodburn, J. R.; Ashton, S. E.; Curry, B. J.; Barker, A. J.; Gilson, K. H. ZD1839 (Iressa): An orally active inhibitor of epidermal growth factor signaling with potential for cancer therapy Cancer Res. 2002, 62, 5749-5754
10. Matar, P.; Rojo, F.; Cassia, R.; Moreno-Bueno, G.; Cosimo, S. D.; Tabernero, J.; Guzman, M.; Rodriguez, S.; Arribas, J.; Palacios, J.; Baselga, J. Combined epidermal growth factor receptor targeting with the tyrosine kinase inhibitor gefitinib (ZD1839) and the monoclonal antibody cetuximab (IMC-C225): superiority over single-agent receptor targeting Clin. Cancer Res. 2004, 10, 6487-6501
11. Nakagawa, M.; Nishimura, T.; Teramukai, S.; Tada, H.; Tanaka, F.; Yanagihara, K.; Furuse, K.; Wada, H.; Fukushima, M. Interstitial lung disease in gefitinib-treated Japanese patients with non-small cell lung cancer-a retrospective analysis: JMTO LC03-02 BMC Res. Notes 2009, 2, 157
12. Stamos, J.; Sliwkowski, M. X.; Eigenbrot, C. Structure of the EGF receptor kinase domain alone and in complex with a 4-anilinoquinazoline inhibitor J. Biol. Chem. 2002, 277, 46265-46272
13. Sorbera, L. A.; Castañer, J.; Silvestre, J. S.; Bayes, M. Erlotinib Hydrochloride Drugs Future 2002, 27, 923
14. Dai, Q.; Ling, Y.-H.; Lie, M.; Zou, Y.-Y.; Kroog, G.; Iwata, K. K.; Perez-Soler, R. Enhanced Sensitivity to the HER1/Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Erlotinib Hydrochloride in Chemotherapy-Resistant Tumor Cell Lines Clin. Cancer Res. 2005, 11, 1572-1578
15. Melosky, B.; Agulnik, J.; Assi, H. Retrospective practice review of treatment of metastatic non-small-cell lung cancer with second-line erlotinib Curr. Oncol. 2008, 6, 279-285
16. Kim, S.; Prichard, N. C.; Younes, N. M.; Yazici, D. Y.; Jasser, A. S.; Bekele, N. B.; Myers, N. J. Cetuximab and Irinotecan interact synergistically to inhibit the growth of orthotopic anaplastic thyroid carcinoma xenografts in nude mice Clin. Cancer Res. 2006, 12, 600-607
17. Balin-Gauthier, D.; Delord, J.-P.; Pillaire, M.-J.; Rochaix, P.; Hoffman, J.-S.; Bugat, R.; Cazaux, C.; Canal, P.; Allal, B. C. Cetuximab potentiates oxaliplatin cytotoxic effect through a defect in NER and DNA replication initiation Br. J. Cancer 2008, 98, 120-128
18. Siena, S.; Peeters, M.; van Cutsem, E.; Humblet, Y.; Conte, P.; Bajetta, E.; Comandini, D.; Bodoky, G.; van Hazel, G.; Salek, T.; Wolf, M.; Devercelli, G.; Woolley, M.; Amado, G. R. Association of progression-free survival with patient-reported outcomes and survival: results from a randomised phase 3 trial of panitumumab Br. J. Cancer 2007, 97, 1469-1474
19. Berchuck, A.; Kamel, A.; Whitaker, R.; Kerns, B.; Olt, G.; Kinney, R.; Soper, J. T.; Dodge, R.; Clarke-Pearson, D. L.; Marks, P.; McKenzie, S; Yin, S.; Bast, R. C., Jr. Overexpression of HER-2/neu is associated with poor survival in advanced epithelial ovarian cancer Cancer Res. 1990, 50, 4087-4091
20. Slamon, D. J.; Clark, G. M.; Wong, S. G.; Levin, W. J.; Ullrich, A.; McGuire, W. L. Human breast cancer: correlation of relapse and survival with amplification of the HER-2 / neu oncogene Science 1987, 235, 177-182
21. Gschwind, A.; Fischer, O. M.; Ullrich, A. The discovery of receptor tyrosine kinases: targets for cancer therapy Nature Rev. Cancer 2004, 4, 361-370
22. Baselga, J.; Norton, L.; Albanell, J.; Kim, Y.; Mendelsohn, J. Recombinant humanized anti-HER2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts Cancer Res. 1998, 58, 2825-2831
23. Molina, M. A.; Codony-Servat, J.; Albanell, J.; Rojo, F.; Arribas, J.; Baselga, J. Trastuzumab (herceptin), a humanized anti-Her2 receptor monoclonal antibody, inhibits basal and activated Her2 ectodomain cleavage in breast cancer cells Cancer Res. 2001, 61, 4744-4749
24. Gennari, R.; Menard, S.; Fagnoni, F.; Ponchio, L.; Scelsi, M.; Tagliabue, E.; Castiglioni, F.; Villani, L.; Magalotti, C.; Gibelli, N.; Oliviero, B.; Ballardini, B.; Da Prada, G.; Zambelli, A.; Costa, A. Pilot study of the mechanism of action of preoperative trastuzumab in patients with primary operable breast tumors overexpressing HER2 Clin. Cancer Res. 2004, 10, 5650-5655
25. Marty, M.; Cognetti, F.; Maraninchi, D.; Snyder, R.; Mauriac, L.; Tubiana-Hulin, M.; Chan, S.; Grimes, D.; Anton, A.; Lluch, A.; Kennedy, J.; O'Byrne, K.; Conte, P.; Green, M.; Ward, C.; Mayne, K.; Extra, J. M. Efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: results of a randomized phase II trial by the M77001 Study Group J. Clin. Oncol. 2005, 23, 4265-4274
26. Inoue, K.; Nakagami, K.; Mizutani, M.; Hozumi, Y.; Fujiwara, Y.; Masuda, N.; Tsukamoto, F.; Saito, M.; Miura, S.; Eguchi, K.; Shinkai, T.; Ando, M.; Watanabe, T.; Masuda, N.; Ohashi, Y.; Sano, M.; Noguchi, S. Randomized phase III trial of trastuzumab monotherapy followed by trastuzumab plus docetaxel versus trastuzumab plus docetaxel as first-line therapy in patients with HER2-positive metastatic breast cancer Breast Cancer Res. Treat. 2010, 119, 127-136
27. Rusnak, D. W.; Lackey, K.; Affleck, K.; Wood, E. R.; Alligood, K. J.; Rhodes, N.; Keith, B. R.; Murray, D. M.; Glennon, K.; Knight, W. B.; Mullin, R. J.; Gilmer, T. M. The effects of the novel, reversible epidermal growth factor receptor/ErbB-2 tyrosine kinase inhibitor, GW2016, on the growth of human normal and tumor-derived cell lines in vitro and in vivo Mol. Cancer Ther. 2001, 1, 85-94
28. Wood, E. R.; Truesdale, A. T.; McDonald, O. B.; Yuan, D.; Hassell, A.; Dickerson, S. H.; Ellis, B.; Pennisi, C.; Horne, E.; Lackey, K.; Alligood, K. J.; Rusnak, D. W.; Gilmer, T. M.; Shewchuk, L. A Unique Structure for Epidermal Growth Factor Receptor Bound to GW572016 (Lapatinib): Relationships among Protein Conformation, Inhibitor Off-Rate, and Receptor Activity in Tumor Cells Cancer Res. 2004, 64, 6652-6659
29. Petrov, K. G.; Zhang, Y. M.; Carter, M.; Cockerill, G. S.; Dickerson, S.; Gauthier, C. A.; Guo, Y.; Mook, R. A., Jr.; Rusnak, D. W.; Walker, A. L.; Wood, E. R.; Lackey, K. E. Optimization and SAR for dual ErbB-1/ErbB-2 tyrosine kinase inhibition in the 6-furanylquinazoline series Bioorg. Med. Chem. Lett. 2006, 16, 4686-4691
30. Package Insert Tykerb (Lapatinib); GlaxoSmithKline: Research Triangle Park, NC 27709 USA, 2010.
31. Iqbal, S.; Goldman, B.; Fenoglio-Preiser, C. M.; Lenz, H. J.; Zhang, W.; Danenberg, K. D.; Shibata, S. I.; Blanke, C. D. Southwest Oncology Group study S0413: a phase II trial of lapatinib (GW572016) as first-line therapy in patients with advanced or metastatic gastric cancer. Ann. Oncol. 2011, Epub ahead of print; doi: 10.1093/annonc/mdr021.
32. Whang, Y. E.; Armstrong, A. J.; Rathmell, W. K.; Godley, P. A.; Kim, W. Y.; Pruthi, R. S.; Wallen, E. M.; Crane, J. M.; Moore, D. T.; Grigson, G.; Morris, K.; Watkins, C. P.; George, D. J. A phase II study of lapatinib, a dual EGFR and HER-2 tyrosine kinase inhibitor, in patients with castration-resistant prostate cancer. Urol. Oncol. 2011, Epub ahead of print; doi: 10.1016/j.urolonc.2010.09.018.
33. Mimura, K.; Kono, K.; Maruyama, T.; Watanabe, M.; Izawa, S.; Shiba, S.; Mizukami, Y.; Kawaguchi, Y.; Inoue, M.; Kono, T.; Choudhury, A.; Kiessling, R.; Fujii, H. Lapatinib inhibits receptor phosphorylation and cell growth and enhances antibody dependent cellular cytoxicity (ADCC) of EGFR and HER2 over-expressing esophageal cancer cell lines. Int. J. Cancer 2011, Epub ahead of print; doi: 10.1002/ijc.25896.
34. Ross, H. J.; Blumenschein, G. R., Jr.; Aisner, J.; Damjanov, N.; Dowlati, A.; Garst, J.; Rigas, J. R.; Smylie, M.; Hassani, H.; Allen, K. E.; Leopold, L.; Zaks, T. Z.; Shepherd, F. A. Randomized phase II multicenter trial of two schedules of lapatinib as first- or second-line monotherapy in patients with advanced or metastatic non-small cell lung cancer Clin. Cancer Res. 2010, 16, 1938-1949
35. Ooi, A.; Takehana, T.; Li, X.; Suzuki, S.; Kunitomo, K.; Iino, H.; Fujii, H.; Takeda, Y.; Dobashi, Y. Protein overexpression and gene amplification of HER-2 and EGFR in colorectal cancers: an immunohistochemical and fluorescent in situ hybridization study Mod. Pathol. 2004, 17, 895-904
36. Tsou, H.-R.; Overbeek-Klumpers, E. G.; Hallett, W. A.; Reich, M. F.; Floyd, M. B.; Johnson, B. D.; Michalak, R. S.; Nilakantan, R.; Discafani, C.; Golas, J.; Rabindran, S. K.; Shen, R.; Shi, X.; Wang, Y.-F.; Upeslacis, J.; Wissner, A. Optimization of 6,7-Disubstituted-4-(arylamino)quinoline-3- carbonitriles as Orally Active, Irreversible Inhibitors of Human Epidermal Growth Factor Receptor-2 Kinase Activity J. Med. Chem. 2005, 48, 1107-1131
37. Li, D.; Shimamura, T.; Ji, H.; Chen, L.; Haringsma, H. J.; McNamara, K.; Liang, M.-C.; Perera, S. A.; Zaghlul, S.; Borgman, C. L.; Kubo, S.; Takahashi, M.; Sun, Y.; Chirieac, L. R.; Padera, R. F.; Lindeman, N. I.; Jänne, P. A.; Thomas, R. K.; Meyerson, M. L.; Eck, M. J.; Engelman, J. A.; Shapiro, G. I.; Wong, K.-K. Bronchial and Peripheral Murine Lung Carcinomas Induced by T790M-L858R Mutant EGFR Respond to HKI-272 and Rapamycin Combination Therapy Cancer Cell 2007, 12, 81-93
38. Eskens, F. A. L. M.; Mom, C. H.; Planting, A. S. T.; Gietema, J. A.; Amelsberg, A.; Huisman, H.; van Doorn, L.; Burger, H.; Stopfer, P.; Verweij, J.; de Vries, E. G. A phase I dose escalation study of BIBW 2992, an irreversible dual inhibitor of epidermal growth factor receptor 1 (EGFR) and 2 (HER2) tyrosine kinase in a 2-week on, 2-week off schedule in patients with advanced solid tumours Br. J. Cancer 2008, 98, 80-85
39. Rall, W.; Soyka, R.; Kulinna, C.; Schnaubelt, J.; Sieger, P. Method for the production of amino crotonyl compounds. International Patent Application WO/2005/037824. PCT/EP2004/011378, April 28, 2005.
40. Yokoi, K.; Thaker, P. H.; Yazici, S.; Rebhun, R. R.; Nam, D.-H.; He, J.; Kim, S.-J.; Abbruzzese, J. L.; Hamilton, S. R.; Fidler, I. J. Dual inhibition of epidermal growth factor receptor and vascular endothelial growth factor receptor phosphorylation by AEE788 reduces growth and metastasis of human colon carcinoma in an orthotopic nude mouse model Cancer Res. 2005, 65, 3716-3725
41. Bold, G.; Caprard, H.-G.; Caravatti, G.; Traxler, P. 4-Amino-6-phenyl- pyrrolo[2,3- d ]pyrimidine Derivatives. PCT Int. WO 03/013541, Feb, 2003.
42. Wong, T. W.; Lee, F. Y.; Yu, C.; Luo, F. R.; Oppenheimer, S.; Zhang, H.; Smykla, R. A.; Mastalerz, H.; Fink, B. E.; Hunt, J. T.; Gavai, A. V.; Vite, G. D. Preclinical antitumor activity of BMS-599626, a pan-HER kinase inhibitor that inhibits HER1/HER2 homodimer and heterodimer signaling Clin. Cancer Res. 2006, 12, 6186-6193
43. Mastalerz, H.; Chang, M.; Chen, P.; Dextraze, P.; Fink, B. E.; Gavai, A.; Goyal, B.; Han, W.-C.; Johnson, W.; Langley, D.; Lee, F. Y.; Marathe, P.; Mathur, A.; Oppenheimer, S.; Ruediger, E.; Tarrant, J.; Tokarski, J. S.; Vite, G. D.; Vyas, D. M.; Wong, H.; Wong, T. W.; Zhang, H.; Zhang, G. New C-5 substituted pyrrolotriazine dual inhibitors of EGFR and HER2 protein tyrosine kinases Bioorg. Med. Chem. Lett. 2007, 17, 2036-2042
44. Mastalerz, H.; Chang, M.; Gavai, A.; Johnson, W.; Langley, D.; Lee, F. Y.; Marathe, P.; Mathur, A.; Oppenheimer, S.; Tarrant., J.; Tokarski, J. S.; Vite, G. D.; Vyas, D. M.; Wong, H.; Wong, T. W.; Zhang, H.; Zhang, G. Novel C-5 aminomethyl pyrrolotriazine dual inhibitors of EGFR and HER2 protein tyrosine kinases Bioorg. Med. Chem. Lett. 2007, 17, 2828-2833
45. Mastalerz, H.; Chang, M.; Chen, P.; Fink, B. E.; Gavai, A.; Han, W C.; Johnson, W.; Langley, D.; Lee, F. Y.; Leavitt, K.; Marathe, P.; Norris, D.; Oppenheimer, S.; Sleczka, B.; Tarrant, J.; Tokarski, J. S.; Vite, G. D.; Vyas, D. M.; Wong, H.; Wong, T. W.; Zhang, H.; Zhang, G. 5-((4-Aminopiperidin-1-yl) methyl)pyrrolotriazine dual inhibitors of EGFR and HER2 protein tyrosine kinases Bioorg. Med. Chem. Lett. 2007, 17, 4947-4954
46. Bhattacharya, S. K.; Cox, E. D.; Kath, J. C.; Mathiowetz, A. M.; Morris, J.; Moyer, J. D.; Pustilnik, L. R.; Rafidi, K.; Richter, D. T.; Su, C.; Wessel, M. D. Achieving selectivity between higly homologous tyrosine kinases anovel selective erbB2 inhibitor Biochem. Biophys. Res. Commun. 2003, 307, 267-273
47. Jani, J. P.; Finn, R. S.; Campbell, M.; Coleman, K. G.; Connell, R. D.; Currier, N.; Emerson, E. O.; Floyd, E.; Harriman, S.; Kath, J. C.; Morris, J.; Moyer, J. D.; Pustilnik, L. R.; Rafidi, K.; Ralston, S.; Rossi, A. M.; Steyn, S. J.; Wagner, L.; Winter, S. M.; Bhattacharya, S. K. Discovery and Pharmacologic Characterization of CP-724,714, a Selective ErbB2 Tyrosine Kinase Inhibitor Cancer Res. 2007, 67, 9887-93
48. Ripin, D. H. B.; Bourassa, D. E.; Brandt, T.; Castaldi, M. J.; Frost, H. N.; Hawkins, J.; Johnson, P. J.; Massett, S. S.; Neumann, K.; Phillips, J.; Raggon, J. W.; Rose, P. R.; Rutherford, J. L.; Sitter, B.; Stewart, A. M., III.; Vetelino, M. G.; Wei, L. Evaluation of Kilogram-Scale Sonagashira, Suzuki, and Heck Coupling Routes to Oncology Candidate CP-724,714 Org. Process Res. Dev. 2005, 9, 440-450
49. Lippa, B.; Kauffman, G. S.; Arcari, J.; Kwan, T.; Chen, J.; Hungerford, W.; Bhattacharya, S.; Zhao, X.; Williams, C.; Xiao, J.; Pustilnik, L.; Su, C.; Moyer, J. D.; Ma, L.; Campbell, M.; Steyn, S. The discovery of highly selective erbB2 (Her2) inhibitors for the treatment of cancer Bioorg. Med. Chem. Lett. 2007, 17, 3081-3086
50. Imai, K. Studies on nucleic acid antagonists. VII. Synthesis and characterization of 1,4,6-triazaindenes (5 H -pyrrolo[3,2- d ]pyrimidines) Chem. Pharm. Bull. 1964, 12, 1030-1042
51. A novel HER2 inhibitor TAK-285 overcomes trastuzumab resistance of HER2-overexpressing breast cancer. Hayashi, A.; Tamura, T.; Yusa, T.; Takagi, S.; Ohta, Y. Cancer Res. 2008, 69, Suppl 1, Abstract 3143.
52. Furneaux, R. H.; Tyler, P. C. Improved Syntheses of 3 H,5 H -Pyrrolo[3,2- d ]pyrimidines J. Org. Chem. 1999, 64, 8411-8412
53. Evans, G. B.; Furneaux, R. H.; Hutchison, T. L.; Kezar, H. S.; Morris, P. E., Jr.; Schramm, V. L.; Tyler, P. C. Addition of Lithiated 9-Deazapurine Derivatives to a Carbohydrate Cyclic Imine: Convergent Synthesis of the Aza- C -nucleoside Immucillins J. Org. Chem. 2001, 66, 5723-5730
54. Furneaux, R. H.; Tyler, P. C. PCT Int. WO 00/61783, Oct 2000.
55. Aertgeerts, K.; Skene, R.; Yona, J.; Sang, B.; Zou, H.; Snell, G.; Jennings, A.; Iwamoto, K.; Habuka, N.; Hirokawa, A.; Ishikawa, T.; Tanaka, T.; Miki, H.; Ohta, Y.; Sogabe, S. Structural analysis of the mechanism of inhibition and allosteric activation of the kinase domain of HER2 J. Biol. Chem. 2011, 286, 18756-18765